Cancer Research

Cilta-Cel Redefines Myeloma Treatment with Lasting Remission
Research & Development Cilta-Cel Redefines Myeloma Treatment with Lasting Remission

Imagine a world where a single treatment could halt the relentless cycle of relapse in a disease as challenging as multiple myeloma, a blood cancer notorious for its grim prognosis in advanced stages, offering hope to patients who have exhausted standard therapies. For these patients, the outlook

Healthy Habits and GLP-1 Drugs Boost Heart Health in Diabetes
Research & Development Healthy Habits and GLP-1 Drugs Boost Heart Health in Diabetes

What if a simple combination of daily choices and modern medicine could halve the risk of heart attacks for millions living with Type 2 diabetes? Across the United States, where this condition affects over 30 million people, cardiovascular disease remains the leading cause of death for those

How Do PFAS in Drinking Water Affect Blood Levels in California?
Research & Development How Do PFAS in Drinking Water Affect Blood Levels in California?

Imagine a silent contaminant lurking in the tap water of millions, undetected by taste or smell, yet capable of accumulating in the human body with potential health consequences that could impact generations. Per- and polyfluoroalkyl substances (PFAS), often called "forever chemicals" due to their

How to Navigate FDA Rules for CAR-NK Cell Therapies?
Research & Development How to Navigate FDA Rules for CAR-NK Cell Therapies?

In the rapidly advancing field of cancer treatment, chimeric antigen receptor natural killer (CAR-NK) cell therapies stand out as a groundbreaking approach, offering scalable, off-the-shelf solutions that could transform patient care. These therapies, often developed from induced pluripotent stem

How Does Lipid Reprogramming Drive Renal Cancer Therapy?
Biotech & Bioprocessing How Does Lipid Reprogramming Drive Renal Cancer Therapy?

Lipid reprogramming has emerged as a critical frontier in understanding and treating clear cell renal cell carcinoma (ccRCC), the predominant subtype of kidney cancer that accounts for a significant portion of cases worldwide. This metabolic transformation, where tumor cells drastically alter how

Uncovering Chemoresistance in BRCA2-Deficient Tumors
Research & Development Uncovering Chemoresistance in BRCA2-Deficient Tumors

What happens when a tumor outsmarts the very treatments designed to destroy it, turning a lifeline into a losing battle for countless patients? In the relentless fight against breast and ovarian cancers tied to BRCA2 deficiencies, a staggering reality emerges: chemotherapy often fails as tumors

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later